Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
暂无分享,去创建一个
J. Barberà | H. Ghofrani | A. Frost | G. Simonneau | M. Hoeper | V. McLaughlin | Julia H N Harris | L. Rubin | J. Vachiéry | M. Kuwana | A. Peacock | C. Blair | K. Miller | N. Galiè | H. Gillies | J. Langley | J. Coghlan | J. Vachiéry | K. L. Miller
[1] Stefan L. Zimmerman,et al. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[2] A. Praestgaard,et al. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[3] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.
[4] R. Benza,et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[6] R. Benza,et al. Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry , 2014, Chest.
[7] M. Humbert,et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. , 2013, Arthritis and rheumatism.
[8] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[9] M. Hudson,et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension , 2012, European Respiratory Journal.
[10] A. Langer,et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH , 2011, Annals of the rheumatic diseases.
[11] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[12] B. Dijkmans,et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy , 2009, European Respiratory Journal.
[13] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[14] Y. Allanore,et al. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials , 2007, Annals of the rheumatic diseases.
[15] R. Barst,et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.
[16] M. Humbert,et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.
[17] S. Rich,et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.
[18] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[19] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[20] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[21] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.